Disease · MONDO_0004986

urinary bladder carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. urinary bladder carcinoma. Diseases, record MONDO_0004986. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004986

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: urinary bladder carcinoma; Open Targets
Open Targets ID: MONDO_0004986; Open Targets
Other names: bladder carcinoma, carcinoma bladder, carcinoma of bladder, carcinoma of the bladder, carcinoma of the urinary bladder, carcinoma of urinary bladder; Open Targets
Disease Ontology: DOID:4007; Disease Ontology
NCI Thesaurus: C4912; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 159 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs159

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BCG VACCINE	CHEMBL2108905	Vaccine component	Approval	TTD	6	5	1	Drugs and targets
ERDAFITINIB	CHEMBL3545376	Small molecule	Approval	TTD	5	4	4	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
AMINOLEVULINIC ACID HYDROCHLORIDE	CHEMBL1200582	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VALRUBICIN	CHEMBL1096885	Small molecule	Approval	TTD	1	0	0	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	31	30	30	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov and TTD	9	7	7	Drugs and targets

1 to 10 of 159

See all 159 drugs

Targets116

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	12	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	8	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 116

See all 116 targets

Trials159

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01968109	An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Phase 1/2	1,482	2026-01-06	Neoplasms by Site	NIVOLUMAB, RELATLIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors	Phase 1/2	1,163	2020-03-24	Advanced or Metastatic Solid Tumors	COBIMETINIB, IPILIMUMAB, NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03732677	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	Phase 3	1,063	2025-07-03	Muscle Invasive Bladder Cancer	CISPLATIN, DURVALUMAB, GEMCITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02554812	A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)	Phase 1/2	409	2024-07-30	Advanced Cancer	AVELUMAB, IVUXOLIMAB, UTOMILUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03219333	A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer	Phase 2	219	2021-12-17	Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms	ENFORTUMAB VEDOTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01976741	Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)	Phase 1	168	2020-04-28	Neoplasms	ROGARATINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02737475	An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread	Phase 1/2	166	2022-01-25	Advanced Cancer	BMS-986178, IPILIMUMAB, NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02030067	Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies	Phase 1/2	127	2023-12-06	Solid Tumor, Metastatic Bladder Cancer	RODUCITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02240238	Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer	Phase 1/2	119	2025-01-22	Solid Tumors	DEMPLATIN PEGRAGLUMER, GEMCITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00978250	A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	Phase 2	95	2019-12-27	Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms	DOXECITINE, TETRAHYDROURIDINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 159

See all 159 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Proportion of Patients Who Undergo Cystectomy	469 of 533	441 of 530	1,063	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Pathologic Complete Response (pCR) Rates at Time of Cystectomy	199 of 533	146 of 530	1,063	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause	27 of 533	29 of 526	1,059	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events	326 of 530	287 of 526	1,056	NCT03732677	Trial comparisons
Enfortumab Vedotin - Cohort 1 vs Enfortumab Vedotin - Cohort 2: deaths from any cause	104 of 125	72 of 89	214	NCT03219333	Trial comparisons
Enfortumab Vedotin - Cohort 1 vs Enfortumab Vedotin - Cohort 2: serious adverse events	59 of 125	35 of 89	214	NCT03219333	Trial comparisons
HER2+ :RT, Paclitaxel, and Trastuzumab vs HER2- :RT and Paclitaxel: Acute Treatment-related Toxicity	7 of 21	14 of 47	68	NCT00238420	Trial comparisons
HER2+ :RT, Paclitaxel, and Trastuzumab vs HER2- :RT and Paclitaxel: Treatment Completion	13 of 21	34 of 47	68	NCT00238420	Trial comparisons
HER2+ :RT, Paclitaxel, and Trastuzumab vs HER2- :RT and Paclitaxel: serious adverse events	6 of 21	15 of 47	68	NCT00238420	Trial comparisons
Group I (Erlotinib Hydrochloride) vs Group II (Placebo): deaths from any cause	0 of 24	0 of 13	37	NCT02169284	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials141

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38940019	RESULT	1	PubMed
38837078	RESULT	1	PubMed
37988648	RESULT	1	PubMed
34740921	RESULT	1	PubMed
31894292	RESULT	1	PubMed
31882719	RESULT	2	PubMed
31831767	RESULT	2	PubMed
31533931	RESULT	2	PubMed
31405822	RESULT	1	PubMed
31101621	RESULT	2	PubMed

1 to 10 of 141

See all 141 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004986

GET https://conductscience.org/api/diseases/v1/MONDO_0004986/drugs?page=2

API reference For AI assistants